

**8<sup>th</sup> September 2009**

**REGEN THERAPEUTICS PLC**  
(“ReGen” or the “Company”; Ticker: (RGT))

**TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES**

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):	<b>ReGen Therapeutics Plc</b>
2. Reason for the notification:	<b>An event changing the breakdown of voting rights</b>
3. Full name of person(s) subject to the notification obligation (iii):	<b>Tigran Kalaydjian</b>
4. Full name of shareholder(s) (if difference from 3):	<b>Unokal Ltd, Clariant Foundation</b>
5. Date of the transaction and date on which the threshold is crossed or reached (v):	<b>8<sup>th</sup> September 2009</b>
6. Date on which issuer notified:	<b>8<sup>th</sup> September 2009</b>
7. Threshold(s) that is/are crossed or reached:	<b>3% to 2%</b>
8. Notified details	
A: Voting rights attached to shares	
Class/type of share if possible using the ISIN Code	<b>GB0004468319</b>
Situation Previous to the triggering transaction (vi) – Number of Shares	<b>1,000,000</b>
Number of Voting Rights (viii)	<b>1,000,000</b>
Resulting situation after the triggering transaction (viii) – Number of Shares	<b>1,000,000</b>
Number of Voting Rights – Direct (x)	<b>N/A</b>
Number of Voting Rights – Indirect (xi)	<b>1,000,000</b>
% of voting rights – Direct	<b>N/A</b>
% of voting rights – Indirect	<b>2.92</b>
B: Financial Instruments	
Resulting situation after the triggering transaction (xii)	
Type of financial instrument	<b>N/A</b>
Expiration date (xiii)	<b>N/A</b>
Exercise/Conversion Period/Date (xiv)	<b>N/A</b>
Number of voting rights that may be acquired if the instrument is exercised/converted	<b>N/A</b>
% of voting rights	<b>N/A</b>

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	N/A
Exercise Price	N/A
Experation Date	N/A
Number of voting rights	N/A
Instrument refers to	
% of voting rights	N/A

Total (A+B+C)

Number of voting rights	1,000,000
% of voting rights	2.92

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): **Unokal Ltd, Clariant Foundation**

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A
13. Additional information:	N/A
14. Contact name:	
15. Contact telephone number:	

**For further information:**

For further information, please contact:

Percy Lomax  
ReGen Therapeutics Plc  
Tel: 020 7153 4920

Roland Cornish/Felicity Geidt  
Beaumont Cornish Limited  
Tel: 020 7628 3396